PTIX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 10:21):

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders...

Stats
Today's Volume	10 819.00
Average Volume	11 579.00
Market Cap	6.23M
EPS	$0 ( 2024-04-02 )
Next earnings date	( $0 ) 2024-05-15
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.220
ATR14	$0.0770 (5.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Wright Timothy R	Buy	21 250	PTIX Common stock Options
2024-03-25	Stein Robert Benjamin	Buy	75 000	PTIX Common stock Options
2024-03-25	Barrage Khalil	Buy	22 500	PTIX Common stock Options
2024-03-25	Buell Jennifer	Buy	75 000	PTIX Common stock Options
2024-03-25	Armen Garo H	Buy	250 000	PTIX Common stock Options

INSIDER POWER
100.00
Last 91 transactions
Buy: 6 726 731 \| Sell: 101 568 933

Protagenic Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Protagenic Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-28 218.00 (0.00 %)
EPS:	$-1.150

Q4	2023
Revenue:	$3 200.00
Gross Profit:	$-23 418.00 (-731.81 %)
EPS:	$-0.380

Q3	2023
Revenue:	$0
Gross Profit:	$-1 419.00 (0.00 %)
EPS:	$-0.320

Q2	2023
Revenue:	$0
Gross Profit:	$-91.00 (0.00 %)
EPS:	$-0.280

Financial Reports:

No articles found.

Protagenic Therapeutics,

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.